Rosiglitazone and implications for pharmacovigilance
- 14 June 2007
- Vol. 334 (7606) , 1233-1234
- https://doi.org/10.1136/bmj.39245.502546.be
Abstract
Footnotes Competing interests: None declared. Provenance and peer review: Commissioned; not externally peer reviewed.Keywords
This publication has 8 references indexed in Scilit:
- Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim AnalysisNew England Journal of Medicine, 2007
- Rosiglitazone and Cardiotoxicity — Weighing the EvidenceNew England Journal of Medicine, 2007
- The Record on Rosiglitazone and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2007
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Protecting the Health of the Public — Institute of Medicine Recommendations on Drug SafetyNew England Journal of Medicine, 2006
- Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes MellitusJAMA, 2005
- Lessons from the glitazones: a story of drug developmentThe Lancet, 2001
- Systematic Reviews: Meta-analysis and its problemsBMJ, 1994